PMC3789358_01
Day 11 since initial examination.
CRIM.OPHMED2013-626704.001.jpg
PMC3789358_01_CRIM.OPHMED2013-626704.001.jpg
fig1
The ulcer increased to 4 mm, the infiltrates became deeper involving midstroma, and there was an appearance of a 2 mm hypopyon (Figure 1).
Day 12 since initial examination (Day 1 on Voriconazole).
CRIM.OPHMED2013-626704.002.jpg
PMC3789358_01_CRIM.OPHMED2013-626704.002.jpg
fig2
There was note of a decrease in the size of the ulcer and clearing of the infiltrates with the new treatment regimen (Figure 2).
Day 14 since initial examination (Day 3 on Voriconazole).
CRIM.OPHMED2013-626704.003.jpg
PMC3789358_01_CRIM.OPHMED2013-626704.003.jpg
fig3
There was gradual decrease of the infiltrates and opacity (Figures 3, 4, and 5).
Day 16 since initial examination (Day 5 on Voriconazole).
CRIM.OPHMED2013-626704.004.jpg
PMC3789358_01_CRIM.OPHMED2013-626704.004.jpg
fig4
There was gradual decrease of the infiltrates and opacity (Figures 3, 4, and 5).
Day 22 since initial examination (Day 11 on Voriconazole).
CRIM.OPHMED2013-626704.005.jpg
PMC3789358_01_CRIM.OPHMED2013-626704.005.jpg
fig5
There was gradual decrease of the infiltrates and opacity (Figures 3, 4, and 5).
Day 29 since initial examination (Day 18 on Voriconazole).
CRIM.OPHMED2013-626704.006.jpg
PMC3789358_01_CRIM.OPHMED2013-626704.006.jpg
fig6
Final visual acuity after 29 days of treatment was 20/40 with note of a slight corneal haze in the area of the previous ulcer (Figure 6).